報價延遲最少15分鐘:2024/10/31 19:58 EDT
|
|
|
|
|
||||||||||||
|
|
|
|
|
58.04 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-5.13/-4.70
|
|
企業價值
2.25B
|
| 資產負債 |
|
每股賬面淨值
11.22
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
151.00K
|
|
每股收益
0.00
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2024/10/31 19:58 EDT
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis. |